人福医药：子公司撤回药品注册申请

Core Viewpoint - The company announced that its subsidiary, Wuhan Guanggu Renfu Biopharmaceutical Co., Ltd., has received a termination notice from the National Medical Products Administration regarding the withdrawal of its drug registration application for the recombinant plasmid-hepatocyte growth factor injection [1] Group 1 - The subsidiary has officially withdrawn its application for the recombinant plasmid-hepatocyte growth factor injection [1]